- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03590652
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)
Study Overview
Status
Conditions
Detailed Description
The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.
The drugs being used in this study are daratumumab ixazomib, pomalidomide, and dexamethasone. Ixazomib may stop the growth of cancer by interfering with proteasomes (the protein breakdown mechanism in the cells). Pomalidomide, and dexamethasone are standard drugs that can change and regulate the immune system and may stop cancer cells from growing. Both Ixazomib and Daratumumab are approved for use in Multiple Myeloma, but not in this combination.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- UCSD Moores Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All participants must be registered into the mandatory POMALYST REMS program and be willing and able to comply with the requirements of the POMALYST REMS program.
- Confirmed diagnosis of Multiple Myeloma having received 1 and 3 prior lines of treatment
- Relapsed and/or refractory disease
- Measurable disease
- Life expectancy of more than 3 months
- ECOG performance status of 0, 1, or 2
- No prior progression on pomalidomide
- All pts must have received prior lenalidomide therapy and been determined to be relapsed and/or refractory.
- Adequate hepatic function
- Adequate renal function
Additional Laboratory Requirements
- ANC ≥1.0 x 10^9/L, Hgb ≥8 g/dL (transfusion permitted)
- Platelet count ≥75 x 10^9/L (≥ 50x10^9/L if bone marrow plasma cells are ≥50% of cellularity)
- Women of child-bearing potential and men with partners of child-bearing potential must agree to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity from the time of signing the informed consent for through 120 days after the last dose of study medication.
- Women of childbearing potential have negative pregnancy test within 72 hours of initiating study drug dosing.
- Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential even if they have had a successful vasectomy starting with the first dose of study therapy through 120 days after the last dose of study therapy.
- All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
- Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the POMALYST REMS program.
- Subjects must agree to take enteric-coated aspirin 81 mg orally daily, or if history of prior thrombotic disease, must be fully anticoagulated with warfarin (INR 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism (PE) at the investigator's discretion.
Exclusion Criteria:
- Current or anticipated use of other investigational agents.
- Prior daratumumab or ixazomib use
- Patients who are refractory to pomalidom
- Non-secretory or hyposecretory multiple myeloma defined as:
- Plasma cell leukemia (>2.0 x 10 9/L circulating plasma cells by standard differential)
- Waldenström's macroglobulinemia or IgM myeloma
- Known central nervous system involvement by multiple myeloma
- Radiotherapy to multiple sites or immunotherapy within 2 weeks before enrollment (localized radiotherapy to a single site at least 1 week before start is permissible)
- Participation in an investigational therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greater. Non-interventional trials (i.e. observational trials) are permitted at any time point
- Female patients who are lactating or have a positive serum pregnancy test during the screening period.
- Major surgery within 3 weeks prior to first dose
- Myocardial infarction within 6 months prior to enrollment, NYHA (New York Heart Association) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
- Systemic treatment, within 14 days before the first dose of ixazomib, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort.
- Known or suspected HIV infection, known HIV seropositivity
- Active hepatitis infection
- Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
- Subjects with known or suspected light chain amyloidosis of any organ.
- Known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, Daratumumab, or its excipients. or known sensitivity to mammalian-derived products.
- Has known chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal
- Has known moderate or severe persistent asthma within the past 2 years per asthma guidelines
- Known gastrointestinal disease or procedure that could interfere with the oral absorption or tolerance of ixazomib or pomalidomide, including difficulty swallowing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ixazomib, daratumumab, pomalidomide and dexamethasone
Daratumumab will be administered at 16mg/kg IV weekly x 8 weeks, biweekly x 8 weeks, then monthly.
Pomalidomide 4mg will be administered orally daily for days 1-21.
Patients ≤ age 75 will receive a 40mg dose of dexamethasone, and those over the age of 75 may receive a 20mg dose of dexamethasone orally on days 1, 8, 15, and 22 (weekly).
Ixazomib will be administered 4mg orally on days 1, 8 and 15.
|
4mg PO days 1,8,15 on 28-day cycle
Other Names:
4mg days PO 1-21/28 days
Other Names:
40mg** PO weekly ** starting dose for age >75 may be 20mg
Other Names:
1800mg SQ weekly x 8 weeks, biweekly x 8 doses, then monthly
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: 2 years
|
Treatment-emergent Grade 2-5 adverse events (AEs) will be assessed using NCI CTCAE v4.03 toxicity criteria
|
2 years
|
Overall Response Rate
Time Frame: 2 years
|
Anti-cancer response as defined by the International Uniform Response Criteria Consensus Recommendations
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical benefit rate
Time Frame: 2 years
|
CBR: minimal response +ORR
|
2 years
|
Progression free survival (PFS)
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Progression-free survival (PFS) is defined as the duration of time from start of treatment until objective tumor progression or death
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Time to progression
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Time to progression is defined as the duration of time from start of treatment until objective tumor progression.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Overall survival (OS)
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Overall survival is defined as the duration of time from start of treatment to death
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Quality of life (QOL) scores
Time Frame: 2 years
|
Cancer Therapy Satisfaction Questionnaire and EORTC QLQ-MY20
|
2 years
|
Minimal Residual Disease (MRD)
Time Frame: 1 year
|
Assessment on the presence of minimal residual disease for those in stringent complete response
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Caitlin Costello, MD, University of California, San Diego
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Pomalidomide
- Daratumumab
- Ixazomib
Other Study ID Numbers
- 180638
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory Multiple Myeloma
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
Carl Ola Landgren, MD, PhDBristol-Myers SquibbRecruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
AmgenCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaCanada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
-
Regeneron PharmaceuticalsActive, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; H. Lee Moffitt...CompletedMultiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Ionis Pharmaceuticals, Inc.Active, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
TakedaCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States, Canada
-
BeBetter Med IncCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Non-Hodgkin's LymphomaChina
Clinical Trials on Ixazomib
-
Mayo ClinicTakedaCompleted
-
Millennium Pharmaceuticals, Inc.Completed
-
SCRI Development Innovations, LLCMillennium Pharmaceuticals, Inc.CompletedMultiple MyelomaUnited States
-
Millennium Pharmaceuticals, Inc.CompletedLymphoma | Advanced Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors | Hematologic MalignanciesUnited States
-
Millennium Pharmaceuticals, Inc.CompletedFollicular LymphomaUnited States, United Kingdom, Belgium, Canada
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Non-hematologic MalignanciesUnited States, Canada
-
Multiple Myeloma Research ConsortiumEli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaboratorsRecruitingRelapsed Refractory Multiple MyelomaUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
University of Wisconsin, MadisonMillennium Pharmaceuticals, Inc.Completed